Preclinical CRC model and retrospective studies have identified new potential prognostic and predictive targets, such as EphA2/EFNA1/EGFR/PTPN12/ATF2/mir-200a/mir-26b, which could be helpful in selecting CRC patients with poor prognosis and Cetuximab (CTX)-resistance [201]. The gene discussed is EFNA1; the disease is colorectal carcinoma.